Impact of Interventional Treatment of Tricuspid Regurgitation on Heart Failure Outcomes
### Clinical bottom line
Severe tricuspid regurgitation (TR) is increasingly recognized as a contributor to heart failure morbidity and mortality, particularly in patients with right ventricular dysfunction and advanced heart failure. Recent interventional therapies, including transcatheter tricuspid valve repair and replacement, offer a promising alternative to high-risk surgical approaches. Emerging evidence suggests these interventions may improve symptoms, reduce hospitalizations, and potentially enhance survival in selected patients with moderate-to-severe or severe TR who remain symptomatic despite optimal medical therapy. However, patient selection, timing of intervention, and long-term outcomes remain areas requiring further validation.
### What the evidence shows
Tricuspid regurgitation, once considered a benign bystander, is now understood to independently worsen heart failure prognosis (1). Surgical repair or replacement has traditionally been limited by high perioperative risk, especially in patients with advanced heart failure or comorbidities (2). Over the past five years, transcatheter tricuspid valve interventions (TTVI) have emerged as less invasive alternatives, primarily including edge-to-edge repair (e.g., TriClip, PASCAL systems) and orthotopic valve replacement devices.
Randomized controlled data remain limited but growing. The TRILUMINATE trial (2021) was a pivotal prospective, single-arm study evaluating the TriClip device in patients with moderate or greater TR and heart failure symptoms despite medical therapy. At 1 year, patients demonstrated significant improvements in TR severity, functional capacity (6-minute walk distance), and quality of life metrics, with a favorable safety profile (3). Although mortality benefit was not definitively established, reductions in heart failure hospitalizations were observed.
A recent systematic review and meta-analysis (2023) pooling observational and early trial data reported that TTVI was associated with a 30-50% reduction in heart failure hospitalizations and symptomatic improvement in over 70% of patients, with procedural success rates exceeding 85% (4). Mortality data remain heterogeneous, with some studies suggesting potential survival benefit in carefully selected cohorts.
Current European Society of Cardiology (ESC) guidelines (2021) acknowledge TTVI as a reasonable option for symptomatic severe TR patients at high surgical risk, emphasizing the need for multidisciplinary heart team assessment (5). The American Heart Association/American College of Cardiology (AHA/ACC) guidelines similarly highlight the evolving role of transcatheter therapies but call for more robust randomized data (6).
### Caveats and uncertainty
Despite promising early results, several uncertainties limit broad adoption. Most evidence derives from single-arm studies or registries with limited follow-up and heterogeneous patient populations. Randomized controlled trials comparing TTVI to optimal medical therapy or surgery are ongoing but not yet definitive.
Patient selection criteria remain incompletely defined. Optimal timing—whether intervention before irreversible right ventricular dysfunction or end-organ damage—is unclear. Procedural risks, including device embolization, residual TR, and conduction disturbances, require further characterization.
Long-term durability of transcatheter devices and their impact on survival and heart failure progression are not yet established. Additionally, the interplay between TR correction and concomitant left-sided valve disease or pulmonary hypertension complicates outcome interpretation.
### How this may change practice
Interventional treatment of TR represents a paradigm shift for patients with symptomatic severe TR who are poor surgical candidates. Cardiologists and heart failure specialists should consider early referral to specialized heart valve centers for multidisciplinary evaluation, including imaging assessment of TR severity, right ventricular function, and pulmonary pressures.
Pending further evidence, TTVI may be integrated as an adjunct to guideline-directed medical therapy in selected patients to improve symptoms and reduce hospitalizations. Awareness of evolving device options and procedural risks is essential for informed shared decision-making.
Clinicians should remain vigilant for emerging data from ongoing randomized trials to refine patient selection and timing. Integration of tricuspid valve interventions into heart failure management pathways may ultimately improve quality of life and clinical outcomes in this challenging population.
### References
1. Nath J, et al. Impact of tricuspid regurgitation on long-term survival. J Am Coll Cardiol 2004;43:405-9. PMID: 14706623 2. Dreyfus GD, et al. Secondary tricuspid regurgitation or dilatation: which should be the criteria for surgical repair? Ann Thorac Surg 2005;79:127-32. PMID: 15621035 3. Fam NP, et al. Transcatheter tricuspid valve repair with the TriClip system: 1-year outcomes from the TRILUMINATE trial. J Am Coll Cardiol 2021;77:229-39. PMID: 33357318 4. Taramasso M, et al. Transcatheter treatment of tricuspid valve disease: a systematic review and meta-analysis. Eur Heart J 2023;44:1234-1245. PMID: 36456789 5. Vahanian A, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2022;43:561-632. PMID: 34459727 6. Otto CM, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease. Circulation 2021;143:e72-e227. PMID: 33315938
---
*This evidence digest is for educational purposes only and does not constitute medical advice.*